newsfilter
← Latest News
Earnings Call Transcripts·

PROKIDNEY CORP. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - PROKIDNEY CORP

  • Financial Performance:

    • The transcript contains no specific disclosed revenue, earnings, profit margins, cash flow, debt, or deferred revenue figures; the company is pre-revenue in a clinical development phase.
    • Economic value modeling suggests potential savings of $200,000 annually per patient by avoiding dialysis, with current US dialysis costs cited at $100,000 (Medicare) to >$200,000 (private payers) per year.
    • Peer pricing for recently launched cell therapies and kidney disease treatments (e.g., IgAN) are cited in the $400,000–$500,000 range annually.
    • The company plans to scale manufacturing from 350 doses annually at launch to 500 within a year, and potentially 3,000 doses within a few years via facility expansion and CDMOs.
    • Scaling beyond current capacity will require additional investment via dilution, debt, or partnerships.
  • Guidance and Future Outlook:

    • Timeline: Enrollment concluded in August 2024; anticipated completion in Q1 2025. Accelerated approval readout (surrogate endpoint) expected in Q2 2027. BLA filing targeted for Q1 2028.
    • Confirmatory Data: Full approval data (time-to-event composite) expected in the second half of 2029.
    • Market Goal: Focused on delaying dialysis or transplant for the 1 million US patients with advanced diabetic kidney disease (CKD stage 3b/4) on standard of care.
    • Future Product Line: Management intends to focus exclusively on advanced diabetic CKD for the near term, with no immediate plans to move upstream or expand to new indications to avoid distraction.
  • Business Segments and Product Lines:

    • Core Asset: RuparinCell (Rilparencel), an autologous cell therapy consisting of a single-course treatment (two injections, 3 months apart).
    • Clinical Progress: Phase III trial (007) enrolled >320 patients for the accelerated approval cohort, with total enrollment expected to exceed 500 patients.
    • Mechanism: Demonstrated attenuation of oxidative damage and pro-inflammatory signaling via a paracrine mechanism (systemic effect from localized injection).
    • Manufacturing: Proprietary facility in North Carolina (owns all manufacturing); transitioned from fresh to cryopreserved product for Phase III to ensure consistency.
    • Secondary Endpoint: Secondary endpoints for accelerated approval may be shared at Q2 2027; full details and publication expected at ASN Kidney Week 2027.
  • Market and Competitive Landscape:

    • Current Standard of Care: Patients are treated with four pillars: RAAS inhibitors (ACE/ARB), SGLT2 inhibitors, non-steroidal MRAs, and GLP-1s, yet residual risk of progression remains.
    • Target Population: Sub-fraction of the 1 million US patients with advanced CKD who continue to progress despite standard of care; characterized by high comorbidity burdens (8–12 daily medications).
    • Competitive Advantage: RuparinCell is a non-chronic, one-to-two-time therapy versus daily oral regimens, potentially offering higher adherence and differentiating value for patients with complex medication schedules.
    • Payer Dynamics: High value proposition centered on avoiding high-cost dialysis; international dialysis costs vary, with some European countries exceeding US costs.
  • Risks and Challenges:

    • Manufacturing Capacity: Current capacity (350 doses at launch) significantly lags behind total potential market size (1 million patients), necessitating rapid scaling.
    • Clinical Risks: Specific focus on safety events related to kidney biopsies (bleeding, infection, hematomas) and potential off-target effects, though current data shows no unusual severe adverse events (SAEs).
    • Statistical Risks: Study powered on conservative assumptions (1.5 mL/min decline in treatment group vs. 3.0 mL/min in sham); Phase II data showed stronger efficacy (4.5 mL/min difference).
    • Regulatory Uncertainty: Accelerated approval relies on surrogate endpoints (eGFR slope); confirmatory clinical benefit (composite events) must be validated by 2029 to maintain full approval.
    • Enrollment Delays: Increased recruitment demand pushed final enrollment to Q1 2025, delaying the BLA submission to Q1 2028 due to concurrent manufacturing validation requirements.
  • Management Commentary and Tone:

    • Confidence: Management expressed strong confidence in the conservative statistical assumptions and the translatability of eGFR slope data to long-term clinical events.
    • Tone: Professional and transparent regarding manufacturing bottlenecks and the necessity of capital raising for future scaling.
    • Strategic Focus: CEO Bruce Culleton emphasized a singular focus on the advanced diabetic CKD market to ensure execution excellence before considering other opportunities.
  • Analyst Questions and Answers:

    • Pricing: Analyst Andrew Tsai queried pricing for a billion-dollar peak sales target; CFO James Coulston referenced dialysis cost avoidance ($200k+/year) and peer cell therapy pricing ($400k–$500k/year) as benchmarks.
    • Trial Design: Clarification provided that the RMAT designation was based on Phase II (002) data without a sham group, whereas Phase III includes a sham arm for the primary analysis.
    • Patient Subsets: Confirmed that the 320-patient accelerated approval cohort includes all patients receiving at least one injection; confirmatory analysis will include the full >500 patient population.
    • Dosing Efficacy: Management believes two injections yield superior efficacy compared to one, with <3% dropout rate between first and second injection (97% adherence).
    • Event Rates: Confirmatory trial powered on a hazard ratio of 0.6, assuming 10–12 composite events per 100 patient years.
  • Other Key Points:

    • Compliance: The company owns its manufacturing facilities, having recently expanded into an adjacent building to increase capacity to 500 doses annually within a year.
    • Safety Profile: While the patient population has high comorbidities leading to SAEs, the trial has not observed SAEs unusual to the disease state itself, with focus strictly on biopsy-related complications.
    • Publication Strategy: Anticipates a simultaneous publication at ASN Kidney Week 2027, coinciding with the release of detailed safety and efficacy data.
    • Data Protection: Management declined to provide specific hazard ratios or confirmatory data previews prior to the official 122-event milestone to avoid "burning alpha."
Company
PROKIDNEY CORP
Keywords
PROKIDNEY CORP